Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy.
Document Type
Article
Publication Date
7-15-2020
Publication Title
Clinical Case Reports
Abstract
Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.
Volume
8
Issue
9
First Page
1797
Last Page
1801
Recommended Citation
Al-Katib AM, Gaith H, Sano D, Al-Katib S, Bonnett M, Kafri Z. Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy. Clin Case Rep. 2020 Jul 15;8(9):1797-1801. doi: 10.1002/ccr3.3019. PMID: 32983498; PMCID: PMC7495781.
DOI
10.1002/ccr3.3019
ISSN
2050-0904
PubMed ID
32983498
COinS